Iantrek, Inc. announced the official US commercial launch of AlloFlo Uveo, a first-of-its-kind surgical treatment targeting the uveoscleral pathway, the company said in a press release.

AlloFlo Uveo provides a bio-interventional approach for enhancing aqueous outflow in patients with glaucoma. AlloFlo Uveo is tailored to maintain the patency of a surgically created cleft accessing the uveoscleral pathway, which offers surgeons and patients a new option in the fight against irreversible vision loss, the company said in the press release. 

At the AAO Annual Meeting this week in Orlando, Florida, Iantrek said it will showcase its portfolio of products, celebrate early clinical adopters, and feature surgical pearls and insights from surgeons who participated in their early-release program.